A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
A phase 1/2 trial of Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, now recruiting.
Overview
A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06868199 by LaNova Medicines Limited, with 87 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-08-01. Interventions recorded: LM-168 and Toripalimab.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-24C5 For Advanced Solid Tumors
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of LM-299 in Subjects Advanced Malignant Tumors
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-350 in Subjects With Advanced Solid Tumours
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase II Study of LM-24C5
Shares LaNova Medicines, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
Shares LaNova Medicines, Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.